Medicus Pharma Ltd (MDCX) AI Stock Analysis

• Market Cap: $48.28M
• Dividend Yield: N/A
• Average Volume (3M): 486.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 15,933,444
• 10 Day Avg. Volume: 672,333
• 30 Day Avg. Volume: 486,210
• PEG Ratio: -0.02
• Price to Book (P/B): 8.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.22
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.16
• 1Y Price Target: $23.50
• Price Target Upside: 383.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 35 Underperform
• Price Target: ―

Medicus Pharma Ltd's financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.

Positive Factors

Clinical Trial Progress

The expansion of the trial to include more patients and additional sites in Europe enhances the company's footprint in the basal cell carcinoma space, potentially attracting partners.

Market Opportunity

The expansion into equine treatment of squamous cell carcinoma could represent a significant market opportunity, potentially reaching $250 million.

Product Development

The Antev acquisition deal will bring on board Teverelix, a next-generation GnRH antagonist that diversifies the Medicus pipeline and adds unlocked value potential.

Negative Factors

Competitive Landscape

AUR recurrence prevention represents a >$2B opportunity with no approved therapies and 500K recurrent patients per year.

Financial Health

Recent financing of $7 million provides Medicus with a financial runway extending into the fourth quarter of 2025 or first quarter of 2026.

Regulatory Uncertainty

A request has been made for a Type C meeting with the FDA.

Medicus Pharma Ltd Business Overview & Revenue Model

Company Description

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

How the Company Makes Money

Medicus Pharma Ltd makes money primarily through the sale of its pharmaceutical products and therapies to healthcare providers, hospitals, and pharmacies. The company generates revenue through direct sales, licensing agreements, and strategic partnerships with other pharmaceutical and biotech companies. Additionally, Medicus Pharma Ltd invests in research and development to discover new treatments, which can lead to new revenue streams through patents and proprietary products. Collaboration with research institutions and participation in clinical trials also contribute to its earnings. By maintaining a robust pipeline of innovative drugs and expanding its market presence, the company aims to sustain and grow its revenue base.

Medicus Pharma Ltd Financial Statement Overview

Summary

Medicus Pharma Ltd faces significant financial challenges with consistent losses and no revenue generation. Despite some balance sheet improvements, the reliance on financing and negative cash flow highlight potential instability.

Income Statement

Medicus Pharma Ltd has shown consistent negative EBIT and net income across multiple years with no revenue reported. This indicates a lack of sales or revenue generation capability, which is a significant concern for future profitability.

Balance Sheet

The company's balance sheet shows improvement in equity from negative to positive over recent years, indicating some financial recovery. However, the historical high liabilities and negative equity in prior years highlight potential financial instability. The current debt-to-equity ratio is low, which is a positive aspect.

Cash Flow

Consistently negative free cash flow indicates ongoing challenges in generating cash from operations. The company relies heavily on financing activities to support operations, which could be unsustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-13.54M	-10.62M	-2.66M	-1.17M	-1.94M
Net Income	-9.36M	-10.62M	-5.31M	-1.69M	-2.06M
Balance Sheet
Total Assets	5.66M	5.65M	1.89M	282.65K	78.51K
Cash, Cash Equivalents and Short-Term Investments	3.98M	4.16M	1.72M	267.65K	78.51K
Total Debt	294.69K	322.27K	0.00	1.53M	667.93K
Total Liabilities	3.51M	2.51M	781.61K	12.48M	10.58M
Stockholders Equity	2.15M	3.13M	1.11M	-12.20M	-10.51M
Cash Flow
Free Cash Flow	-13.01M	-10.25M	-4.16M	-1.06M	-1.45M
Operating Cash Flow	-13.01M	-10.25M	-4.16M	-1.06M	-1.45M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	16.41M	12.69M	5.61M	1.25M	882.38K

Medicus Pharma Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDCX, the sentiment is Negative. The current price of 4.86 is above the 20-day moving average (MA) of 2.89, above the 50-day MA of 3.95, and above the 200-day MA of 3.44, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 49.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDCX.

Medicus Pharma Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WHWK	57 Neutral	$92.81M	12.73	17.69%	―	16.51%	―
Sector *	52 Neutral	$7.51B	0.24	-62.67%	2.30%	16.09%	0.95%
MRSN	44 Neutral	$47.36M	―	-505.14%	―	-11.21%	47.20%
MIST	39 Underperform	$136.87M	―	-307.27%	―	-100.00%	51.19%
MDCX	35 Underperform	$48.28M	―	-1882.04%	―	―	―
RVPH	28 Underperform	$26.60M	―	-916.17%	―	―	45.15%
IMMX		$75.55M	―	-111.42%	―	―	―